The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income (loss) | -167,100 |
| Depreciation and amortization | 106,400 |
| Non cash operating lease costs | 14,700 |
| Deferred income taxes | -4,700 |
| Disposal/impairment of assets | 3,200 |
| Restructuring and other (income) charges, net | 55,700 |
| Cto resales | 0 |
| Lifo liquidation | -6,800 |
| Share-based compensation | 18,300 |
| (gain) loss on strategic investment | -26,200 |
| Pension and other postretirement benefit costs | 1,200 |
| Goodwill impairment charge | 183,800 |
| Impairment, long-lived asset, held-for-use | 109,300 |
| Other non-cash items | -7,600 |
| Accounts receivable, net | -12,200 |
| Inventories, net | -40,200 |
| Prepaid and other current assets | -1,300 |
| Planned major maintenance outage | 6,500 |
| Accounts payable | -2,600 |
| Accrued expenses | -14,100 |
| Accrued payroll and employee benefits | 6,900 |
| Income taxes | -1,200 |
| Operating leases | 19,500 |
| Restructuring and other spending | -46,100 |
| Cto resales | -6,200 |
| Changes in all other operating assets and liabilities, net | -6,600 |
| Net cash provided by (used in) operating activities | 331,200 |
| Capital expenditures | 57,700 |
| Proceeds from disposition of assets | 3,600 |
| Sale (purchase) of strategic investments, net | 16,400 |
| Restricted investment | 13,000 |
| Other investing activities, net | 0 |
| Net cash provided by (used in) investing activities | -57,500 |
| Proceeds from revolving credit facility and other borrowings | 291,300 |
| Payments on revolving credit facility and other borrowings | 483,600 |
| Debt issuance costs | 0 |
| Financing lease obligations, net | -1,300 |
| Tax payments related to withholdings on vested equity awards | 3,700 |
| Proceeds and withholdings from share-based compensation plans, net | 1,400 |
| Repurchases of common stock under publicly announced plan | 56,300 |
| Net cash provided by (used in) financing activities | -252,200 |
| Increase (decrease) in cash, cash equivalents, and restricted cash | 21,500 |
| Effect of exchange rate changes on cash | 4,500 |
| Change in cash, cash equivalents, and restricted cash | 26,000 |
| Cash, cash equivalents, and restricted cash at beginning of period | 86,600 |
| Cash, cash equivalents, and restricted cash at end of period | 112,600 |
Ingevity Corp (NGVT)
Ingevity Corp (NGVT)